InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,308.13
(
0.09%
)
US TECH 100
18,176.00
(
0.58%
)
Dow Jones
39,806.77
(
-0.49%
)
Brent Oil
83.49
(
-0.13%
)
Bitcoin
69,492.31
(
4.86%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

micanwait

Send PM Follow Ignore
Followers 6
Posts 718
Boards Moderated 0
Alias Born 06/22/2011

micanwait

Re: greggors post# 74002

Friday, 06/17/2016 1:38:56 PM

Friday, June 17, 2016 1:38:56 PM

Post# of 80490
Greg..

Its silly. Ariad had a useful drug for immunotherapy and they sold it to Bellicum. $50mil-- which is not peanuts, but I believe they had 10% of BLCM at one time.

This long term plan is just whistling past the graveyard. They seem to have a drug with real value. Denner knows what he has and the rest in just posturing.

He should monetize now and move on. Going long is very risky. Not just the usual biotech risks of bad management, bad trial designs, bad side effects etc.

Perhaps the bigger risk is the looming deflationary recession which could last many years and sink a lot of boats.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up